MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
23.88
-0.32
-1.32%
Pre Market: 23.80 -0.08 -0.34% 06:13 02/12 EST
OPEN
24.23
PREV CLOSE
24.20
HIGH
24.35
LOW
23.27
VOLUME
25
TURNOVER
0
52 WEEK HIGH
46.27
52 WEEK LOW
18.41
MARKET CAP
2.30B
P/E (TTM)
-4.0214
1D
5D
1M
3M
1Y
5Y
1D
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
PR Newswire · 9h ago
Ultragenyx Pharmaceutical Q4 2025 Earnings Preview
Seeking Alpha · 14h ago
Earnings Outlook For Ultragenyx Pharmaceutical
Benzinga · 18h ago
Ultragenyx Faces Securities Class Action Over Alleged Misleading Statements
Reuters · 20h ago
Here are the major earnings after the close Thursday
Seeking Alpha · 21h ago
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
PR Newswire · 22h ago
Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline
PR Newswire · 22h ago
Ultragenyx Faces Setrusumab Lawsuits As UX111 Data Shapes Valuation Debate
Simply Wall St · 1d ago
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.